Monoclonal Antibodies Targeting IL-23 in Ulcerative Colitis Treatment

The chapter explores the nuanced nature of ulcerative colitis as a spectrum of immunological diseases, emphasizing the use of monoclonal antibodies to target specific pathways like T-H17 and IL-23 for more precise and efficient treatment. It also highlights the approval of Rizankizumab, a novel medication focusing solely on blocking IL-23, heralding a move towards personalized therapy in ulcerative colitis.